05.阿里拉姆（ALNY.US）2024年第三季度业绩电话会：公司实现显著业绩增长，总收入达到4.2亿美元，同比增长34%。其中，全球净产品收入同比增长3090万美元，达到4200万美元。在研发方面，公司持续推进多个项目，包括针对ATTR心肌病的潜在变革性药物和早发性阿尔茨海默病的一期研究。此外，公司预计到2025年底将有15个新的专利申请，临床产品线将几乎翻倍。财务方面，自由现金流为负1170万美元，较上季度改善140万美元，展现出公司稳健的财务状况和良好的发展前景。

海量资讯、精准解读，尽在新浪财经APP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.